NCT04892849View on ClinicalTrials.gov

Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

May 31, 2028

Study Completion Date

December 31, 2030

Conditions
HNSCCNSCLCEsophageal CancerUrothelial CarcinomaRenal Cell CarcinomaSquamous Cell Carcinoma of the SkinSmall Cell Bronchial Carcinomas
Interventions
OTHER

Conventional Therapy acc. to prevailing clincal approved schemes

The study is observational. The treatment-plan of the underlying disease remains unchanged. The treatment of the patient is according to the prevailing clinical approved schemes at the respective entities. Blood will be drawn from patients at several time points during and after RT and ICI for detailed immunomonitoring of the patients.

Trial Locations (1)

91054

RECRUITING

Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen

All Listed Sponsors
lead

University of Erlangen-Nürnberg Medical School

OTHER